Adaptive Biotechnologies' clonoSEQ features in about 100 abstracts at ASH 2026
ADPT•Adaptive Biotechnologies will present clonoSEQ findings in approximately 100 abstracts, including 27 oral presentations, at the American Society of Hematology meeting Dec. 12-15, 2026, in New Orleans.
1. ASH presentations
Adaptive Biotechnologies will present clonoSEQ findings across approximately 100 abstracts at the American Society of Hematology meeting, including 27 oral presentations. In 20 biopharma-sponsored studies, measurable residual disease assessment is the primary endpoint in four and a secondary endpoint in 11.
2. Research findings
The research covers multiple myeloma, chronic lymphocytic leukemia and lymphoma. Findings include using clonoSEQ to support treatment adjustment in multiple myeloma and guide treatment duration in chronic lymphocytic leukemia; lymphoma research indicates it can help predict outcomes after initial treatment, complementing imaging. Real-world findings identify patients with sustained disease negativity whose survival matches the general population.




